{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:17:34Z","timestamp":1783495054037,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serum uric acid has been consistently associated with cardiovascular risk, yet whether this relationship reflects independent vascular pathology or cardiometabolic risk clustering remains unresolved. We examined associations of serum uric acid and hyperuricemia with imaging-defined subclinical coronary and carotid atherosclerosis in a large population-based cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from the Paracelsus 10,000 study, a population-based cohort of adults aged 40\u201377\u00a0years recruited from the Austrian national population registry. Coronary artery calcium (CAC) was assessed by computed tomography in 1561 participants with available cardiac computed tomography and polygenic risk score data; carotid plaque burden was assessed by ultrasonography in 8970 participants. Associations were evaluated using ordinal logistic regression \u2014 with CAC categorized by Agatston score (0, 1\u201399, 100\u2013299,\u2009\u2265\u2009300) and carotid plaque burden categorized by total plaque area \u2014 with sequential adjustment for cardiovascular risk score (SCORE2), metabolic syndrome, polygenic cardiovascular risk, lipoprotein(a) and systemic inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher serum uric acid levels were strongly associated with greater CAC burden in unadjusted analyses (OR 1.60 per 1\u00a0mg\/dL, 95% CI 1.48\u20131.74). This association was attenuated but remained significant after adjustment for cardiovascular risk score, metabolic syndrome, polygenic risk, lipoprotein(a), and inflammatory markers (OR 1.26, 95% CI 1.14\u20131.38). Hyperuricemia was independently associated with higher CAC categories after adjustment (OR 1.67, 95% CI 1.20\u20132.32). Carotid plaque burden showed a strong unadjusted association with serum uric acid that was substantially attenuated after multivariable adjustment, although a weak association remained statistically significant (OR 1.06, 95% CI 1.01\u20131.10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum uric acid and hyperuricemia are independently associated with subclinical coronary atherosclerosis beyond established cardiovascular risk factors, genetic susceptibility and systemic inflammation. The attenuation of carotid plaque associations after full adjustment suggests that extracoronary plaque burden is largely driven by cardiometabolic risk clustering rather than urate-specific pathways. These findings position uric acid as a clinically accessible marker of subclinical coronary atherosclerosis and raise the question of whether systematic urate assessment should inform cardiovascular risk stratification beyond established risk scores.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02974-8","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:28:15Z","timestamp":1782721695000},"page":"1424-1435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uric acid and subclinical atherosclerosis: distinct associations across coronary and carotid arteries"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3353-8702","authenticated-orcid":false,"given":"Mathias","family":"Ausserwinkler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8325-250X","authenticated-orcid":false,"given":"Christian","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1609-4676","authenticated-orcid":false,"given":"Bernhard","family":"Paulweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5134-4137","authenticated-orcid":false,"given":"Johannes","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2814-0621","authenticated-orcid":false,"given":"Ludmilla","family":"Kedenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5403-9478","authenticated-orcid":false,"given":"Tobias","family":"Kiesslich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1183-6419","authenticated-orcid":false,"given":"Barbara","family":"Fixl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-2692","authenticated-orcid":false,"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7226-8371","authenticated-orcid":false,"given":"Patrick","family":"Langthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6132-8670","authenticated-orcid":false,"given":"Bernhard","family":"Iglseder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6657","authenticated-orcid":false,"given":"Maria","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0310-0536","authenticated-orcid":false,"given":"Elmar","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4024-0220","authenticated-orcid":false,"given":"Bernhard","family":"Wernly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"14","key":"2974_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"Global Cardiovascular Risk Consortium","year":"2023","unstructured":"Global Cardiovascular Risk Consortium (2023) Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med 389(14):1273\u20131285","journal-title":"N Engl J Med"},{"issue":"1","key":"2974_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","volume":"67","author":"RC Hoogeveen","year":"2021","unstructured":"Hoogeveen RC, Ballantyne CM (2021) Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem 67(1):143\u201353","journal-title":"Clin Chem"},{"issue":"12","key":"2974_CR3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.5551\/jat.RV22043","volume":"32","author":"T Nakahashi","year":"2025","unstructured":"Nakahashi T, Tada H, Sakata K, Takamura M (2025) Gout, uric acid, and coronary artery disease. J Atheroscler Thromb 32(12):1471\u201381","journal-title":"J Atheroscler Thromb"},{"issue":"7","key":"2974_CR4","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300393R","volume":"37","author":"X Wei","year":"2023","unstructured":"Wei X, Zhang M, Huang S, Lan X, Zheng J, Luo H et al (2023) Hyperuricemia: a key contributor to endothelial dysfunction in cardiovascular diseases. FASEB J 37(7):e23012","journal-title":"FASEB J"},{"key":"2974_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2018.10.007","volume":"278","author":"T Maruhashi","year":"2018","unstructured":"Maruhashi T, Hisatome I, Kihara Y, Higashi Y (2018) Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis 278:226\u2013231","journal-title":"Atherosclerosis"},{"issue":"8","key":"2974_CR6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/jcp.31038","volume":"238","author":"B He","year":"2023","unstructured":"He B, Nie Q, Wang F, Wang X, Zhou Y, Wang C et al (2023) Hyperuricemia promotes the progression of atherosclerosis by activating endothelial cell pyroptosis via the ROS\/NLRP3 pathway. J Cell Physiol 238(8):1808\u20131822","journal-title":"J Cell Physiol"},{"issue":"7","key":"2974_CR7","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2307222","volume":"23","author":"Q Guo","year":"2022","unstructured":"Guo Q, Liu Y, Feng X, Yang J, Zhai G, Zhou Y (2022) Serum uric acid and hyperuricemia associate with coronary artery disease among postmenopausal women. Rev Cardiovasc Med 23(7):222","journal-title":"Rev Cardiovasc Med"},{"issue":"11","key":"2974_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0337091","volume":"20","author":"D Lyu","year":"2025","unstructured":"Lyu D, Zhuang R, Li J, Wu Y, Di Y, Song M et al (2025) Association of hyperuricemia with coronary heart disease and other cardiovascular outcomes: a systematic review and dose-response meta-analysis. PLoS One 20(11):e0337091","journal-title":"PLoS One"},{"key":"2974_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2376","volume":"357","author":"X Li","year":"2017","unstructured":"Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JP et al (2017) Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ 357:j2376","journal-title":"BMJ"},{"issue":"10","key":"2974_CR10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/HJH.0000000000003807","volume":"42","author":"E Fiori","year":"2024","unstructured":"Fiori E, De Fazio L, Pidone C, Perone F, Tocci G, Battistoni A et al (2024) Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases. J Hypertens 42(10):1665\u201380","journal-title":"J Hypertens"},{"issue":"1","key":"2974_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/BOR.0000000000000679","volume":"32","author":"K Yip","year":"2020","unstructured":"Yip K, Cohen RE, Pillinger MH (2020) Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol 32(1):71\u20139","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"2974_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.103796","volume":"35","author":"M Kuwabara","year":"2025","unstructured":"Kuwabara M, Hisatome I, Ae R, Kosami K, Aoki Y, Andres-Hernando A et al (2025) Hyperuricemia, a new cardiovascular risk. Nutr Metab Cardiovasc Dis 35(3):103796","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"2974_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11926-024-01151-y","volume":"26","author":"J Held","year":"2024","unstructured":"Held J, Haschka D, Lacaita PG, Feuchtner GM, Klotz W, Stofferin H et al (2024) Review: the role of dual-energy computed tomography in detecting monosodium urate deposits in vascular tissues. Curr Rheumatol Rep 26(8):302\u201310","journal-title":"Curr Rheumatol Rep"},{"issue":"16","key":"2974_CR14","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/jama.2025.0610","volume":"333","author":"P Glynn","year":"2025","unstructured":"Glynn P, Khan SS, Greenland P (2025) Cardiac CT calcium score. JAMA 333(16):1447\u20138","journal-title":"JAMA"},{"issue":"4","key":"2974_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jacc.2018.05.027","volume":"72","author":"P Greenland","year":"2018","unstructured":"Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE (2018) Coronary calcium score and cardiovascular risk. J Am Coll Cardiol 72(4):434\u201347","journal-title":"J Am Coll Cardiol"},{"issue":"10519","key":"2974_CR16","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/S0140-6736(25)01586-7","volume":"406","author":"P van der Bijl","year":"2025","unstructured":"van der Bijl P, Gulati M, Saraste A, Marwick T, Kwong R, Blankstein R et al (2025) Contemporary, non-invasive imaging diagnosis of chronic coronary artery disease. Lancet 406(10519):2577\u20132587","journal-title":"Lancet"},{"issue":"10055","key":"2974_CR17","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK (2016) Gout. Lancet 388(10055):2039\u201352","journal-title":"Lancet"},{"issue":"4","key":"2974_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","volume":"15","author":"AS Agatston","year":"1990","unstructured":"Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr., Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15(4):827\u2013832","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2974_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/gucdd1020009","volume":"1","author":"S Gupta","year":"2023","unstructured":"Gupta S, Miller E, Merkin SS, McMahon M, Karol EW, FitzGerald JD (2023) The risk of cardiovascular disease among male and female participants treated for gout in the Multi-Ethnic Study of Atherosclerosis (MESA). Gout Urate Cryst Depos Dis 1(2):89\u201398","journal-title":"Gout Urate Cryst Depos Dis"},{"issue":"15","key":"2974_CR20","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.jacc.2015.08.035","volume":"66","author":"RL McClelland","year":"2015","unstructured":"McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal RA et al (2015) 10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J Am Coll Cardiol 66(15):1643\u20131653","journal-title":"J Am Coll Cardiol"},{"key":"2974_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cca.2018.05.046","volume":"484","author":"G Ndrepepa","year":"2018","unstructured":"Ndrepepa G (2018) Uric acid and cardiovascular disease. Clin Chim Acta 484:150\u2013163","journal-title":"Clin Chim Acta"},{"key":"2974_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","volume":"80","author":"C Borghi","year":"2020","unstructured":"Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G et al (2020) Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med 80:1\u201311","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2974_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-04055-y","volume":"24","author":"M Hussain","year":"2024","unstructured":"Hussain M, Ghori MU, Aslam MN, Abbas S, Shafique M, Awan FR (2024) Serum uric acid: an independent risk factor for cardiovascular disease in Pakistani Punjabi patients. BMC Cardiovasc Disord 24(1):546","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2974_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semnephrol.2004.10.001","volume":"25","author":"DH Kang","year":"2005","unstructured":"Kang DH, Nakagawa T (2005) Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 25(1):43\u20139","journal-title":"Semin Nephrol"},{"issue":"1","key":"2974_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03348-z","volume":"26","author":"Y Yang","year":"2024","unstructured":"Yang Y, Hu P, Zhang Q, Ma B, Chen J, Wang B et al (2024) Single-cell and genome-wide Mendelian randomization identifies causative genes for gout. Arthritis Res Ther 26(1):114","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"2974_CR26","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1038\/s41588-024-01921-5","volume":"56","author":"TJ Major","year":"2024","unstructured":"Major TJ, Takei R, Matsuo H, Leask MP, Sumpter NA, Topless RK et al (2024) A genome-wide association analysis reveals new pathogenic pathways in gout. Nat Genet 56(11):2392\u20132406","journal-title":"Nat Genet"},{"issue":"18","key":"2974_CR27","first-page":"1","volume":"28","author":"IS Mackenzie","year":"2024","unstructured":"Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A et al (2024) Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation. Health Technol Assess 28(18):1\u201355","journal-title":"Health Technol Assess"},{"issue":"22","key":"2974_CR28","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K et al (2019) Febuxostat for cerebral and cardiorenovascular events prevention study. Eur Heart J 40(22):1778\u201386","journal-title":"Eur Heart J"},{"issue":"1","key":"2974_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2016","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J et al (2016) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342","journal-title":"Ann Rheum Dis"},{"key":"2974_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.7453","author":"E Cipolletta","year":"2026","unstructured":"Cipolletta E, Zverkova Sandstr\u00f6m T, Rozza D, Leyrat C, Nakafero G, Drivelegka P et al (2026) Treat-to-target urate-lowering treatment and cardiovascular outcomes in patients with gout. JAMA Intern Med. https:\/\/doi.org\/10.1001\/jamainternmed.2025.7453","journal-title":"JAMA Intern Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02974-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02974-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:05:16Z","timestamp":1783494316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02974-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2974"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02974-8","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.T. has received personal honoraria for lectures and educational activities from EVER Pharma, Marinus, Arvelle, Angelini, Alexion, Argenx, Medtronic, Biocodex, Bial-Portela & Ca, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova, Eisai, Epilog, UCB, Biogen, Sanofi, Jazz Pharmaceuticals and Actavis. His institution has received research grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF \u00d6sterreichischer Fonds zur Wissenschaftsf\u00f6rderung, the Austrian Federal Ministry for Education, Science and Research, and the Jubil\u00e4umsfonds of the Austrian National Bank. All other authors declare that they have no conflicts of interest and no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}